Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.
Fourati S, Reslan A, Bourret J, Casalegno JS, Rahou Y, Chollet L, Pillet S, Tremeaux P, Dossou NC, Gault E, Salmona M, Imbert-Marcille BM, Mirand A, Larrat S, Moisan A, Marot S, Schnuriger A, Veyrenche N, Engelmann I, Handala L, Henry A, Stephan V, Brichler S, Avettand-Fenoel V, Zemali N, Lefeuvre C, Pronier C, Deroche L, Jaffar-Bandjee MC, Mouna L, Francois C, Regueme A, Hartard C, Rogez S, Gallais F, Ly A, Rodriguez C, Dos Santos G, Simon-Loriere E, Schwartz O, Buchrieser J, Pawlotsky JM, Lemoine F, Audureau E, Rameix-Welti MA; POLYRES investigators.
Fourati S, et al. Among authors: rahou y.
Lancet Infect Dis. 2024 Oct 14:S1473-3099(24)00570-X. doi: 10.1016/S1473-3099(24)00570-X. Online ahead of print.
Lancet Infect Dis. 2024.
PMID: 39419046